Download PDF
Dtsch Med Wochenschr 2020; 145(15): 1051-1056
DOI: 10.1055/a-1164-3960
Dossier

COVID-19 aus Sicht der Infektiologie

COVID-19: Questions and answers from Infectious Diseases Specialty
Elham Khatamzas
,
Camilla Rothe
,
Inge Kroidl
› Further Information
Also available at
   Permissions and Reprints

Corrected by:

COVID-19 aus Sicht der InfektiologieDtsch Med Wochenschr 2020; 145(15): e95-e95
DOI: 10.1055/a-1233-3238

Abstract

The control and management of infection with the novel SARS-CoV-2 virus requires multidisciplinary work between specialists on all levels. This article aims to provide an overview of the current knowledge of COVID-19 from the view of infectious diseases physicians including all the uncertainties of our understanding of the pathogenesis and immunity.

Die SARS-CoV-2-Pandemie stellt die Welt vor beispiellose Herausforderungen. Die besonderen Aspekte der rapiden Ausbreitung des Erregers sowie der Mangel an spezifischen prophylaktischen und therapeutischen Maßnahmen erfordern infektiologische Expertise und interdisziplinäre Zusammenarbeit auf allen Ebenen.

Schlüsselwörter

COVID-19 - Infektiologie - Behandlung - SARS-CoV-2-Serologie

Key words

COVID-19 - infectious Diseases - management - SARS-CoV-2 serology


Publication History

Article published online:
30 July 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Zhou P, Yang XL, Wang XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273
    CrossrefPubMedGoogle Scholar
  • 2 Andersen KG, Rambaut A, Lipkin WI. et al. The proximal origin of SARS-CoV-2. Nat Med 2020; 26: 450-452
    CrossrefPubMedGoogle Scholar
  • 3 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181 (02) 271-280
    CrossrefPubMedGoogle Scholar
  • 4 He X, Lau EHY, Wu P. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26: 672-675
    CrossrefPubMedGoogle Scholar
  • 5 Rothe C, Schunk M, Sothmann P. et al. Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382: 970-971
    CrossrefPubMedGoogle Scholar
  • 6 Liu Y, Ning Z, Chen Y. et al Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020; DOI: 10.1038/s41586-020-2271-3. . Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 7 van Doremalen N, Bushmaker T, Morris D. et al Aerosol and Surface Stability of SARS-CoV-2 as Compared With SARS-CoV-1. N Engl J Med 2020; 382: 1564-1567 . doi:10.1056/NEJMc2004973
    CrossrefPubMedGoogle Scholar
  • 8 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
    CrossrefPubMedGoogle Scholar
  • 9 Tay MZ, Poh CM, Rénia L. et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20: 363-374
    CrossrefPubMedGoogle Scholar
  • 10 Huber TB, Glatzel M, Wichmann D. et al. Correspondence Multiorgan and Renal Tropism of SARS-CoV-2. NEJM May 2020; DOI: 10.1056/NEJMc2011400.
    CrossrefPubMedGoogle Scholar
  • 11 Li J, Zhang L, Liu B. et al. Case Report: Viral Shedding for 60 Days in a Woman with Novel Coronavirus Disease (COVID-19). Am J Trop Med Hyg 2020; 102: 1210-1213
    CrossrefPubMedGoogle Scholar
  • 12 Wölfel R, Corman VM, Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-469
    CrossrefPubMedGoogle Scholar
  • 13 Lin WHW, Kouyos RD, Adams RJ. et al. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A 2012; 109: 14989-14994
    CrossrefPubMedGoogle Scholar
  • 14 Radon K, Saathoff E, Pritsch M. et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19). medRxiv 2020; DOI: 2020.04.28.20082743.
    CrossrefPubMedGoogle Scholar
  • 15 Streeck H, Schulte B, Kuemmerer B. et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. medRxiv 2020; DOI: 2020.05.04.20090076.
    CrossrefPubMedGoogle Scholar
  • 16 Long QX, Liu BZ, Deng HJ. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26 (06) 845-848
    CrossrefPubMedGoogle Scholar
  • 17 Koehler P, Cornely OA, Böttiger BW. et al. Shimabukuro-Vornhagen A. COVID-19 Associated Pulmonary Aspergillosis. Mycoses 2020; 63 (06) 528-534
    CrossrefPubMedGoogle Scholar
  • 18 Lee EYP, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us?. Lancet Infect Dis 2020; 20: 384-385
    CrossrefPubMedGoogle Scholar
  • 19 Vogel-Claussen J, Ley-Zaporozhan J, Agarwal P. et al Recommendations of the Thoracic Imaging Section of the German Radiological Society for clinical application of chest imaging and structured CT reporting in the COVID-19 pandemic. Rofo 2020; DOI: 10.1055/a-1174-8378. . Online ahead of print
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Rawson T, Morre L, Zhu N. et al Bacterial and Fungal co-infection with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa530. . Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 21 Mehra MR, Desai SS, Ruschitzka F. et al Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; DOI: 10.1016/S0140-6736(20)31180-6. . Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 22 Watson J. An open letter to Mehra et al and The Lancet. Im Internet:. https://zenodo.org/record/3862789#.XwW4vygzaUl ; Stand: 29.05.2020
    PubMedGoogle Scholar
  • 23 Mulangu S, Dodd LE, Davey RT. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303
    CrossrefPubMedGoogle Scholar
  • 24 Shen C, Wang Z, Zhao F. et al. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA – J Am Med Assoc 2020; 323: 1582-1589
    CrossrefPubMedGoogle Scholar
  • 25 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490-9496
    CrossrefPubMedGoogle Scholar